In elderly patients with stable coronary artery disease undergoing percutaneous coronary intervention, patients with high serum sclerostin levels had a lower incidence rate of main adverse cardiovascular and cerebrovascular events (MACCEs) (p = 0.014) and better survival (p < 0.05) than those with low serum sclerostin levels [60]. Here, SOST is linked to coronary artery disorder.